99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of ATNX Investors. Click "Join this Class Action" above.


Athenex, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. from August 7, 2019 through February 26, 2021 (the “Class Period”). The lawsuit seeks to recover damages for Athenex, Inc. investors under the federal securities laws.

If you bought Athenex, Inc. securities between August 7, 2019 through February 26, 2021, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Athenex, Inc. – ATNX

New York, N.Y., March 9, 2021. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”).

To join the ATNX class action, go to http://zhanginvestorlaw.com/cases/athenex-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period (1) the data included in the Oral Paclitaxel and Encequidar New Drug Application (“NDA”) presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (2) the uncertainty over the results of the primary endpoint of objective response rate (“ORR”) at week 19 conducted by blinded independent central review (“BICR”); (3) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (4) the Company’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (5) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/athenex-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.